Carotid PET and at-risk patients: Tamarappoo and Hachamovitch provide perspective on current 18F-FDG PET imaging of arterial inflammation and atherosclerosis for identification of vulnerable plaque and cardiovascular risk stratification in asymptomatic patients.
Management change and PET: Hillner and colleagues use administrative claims to categorize type and timing of clinical services delivered in a study designed to assess results of intended management changes with PET imaging.
Dose-intensified 131I-MIBG therapy: Ezziddin and colleagues describe long-term outcomes and toxicities associated with specific doses of systemic 131I-MIBG therapy for neuroendocrine tumors.
PET/CT and HNSCC for follow-up: Paidpally and colleagues determine the prognostic value of 18F-FDG PET/CT for overall survival in head and neck squamous cell cancer when performed with clinical assessment between 4 and 24 months after treatment.
18F-FET PET and glioma progression: Galldiks and colleagues investigate the potential of 18F-FET PET for noninvasive detection of malignant progression in patients with low-grade glioma, for which conventional approaches to progression are challenging.
Fusion SPECT radioembolization dosimetry: Lam and colleagues report on a dual-tracer SPECT fusion imaging protocol that merges data on radioactivity distribution with physiologic liver mapping for 90Y radioembolization planning.
Early PET vs. RECIST: Lastoria and colleagues compare the treatment efficacy prediction capabilities of early 18F-FDG PET/CT and standard dimensional Response Evaluation Criteria in Solid Tumors metrics in patients with resectable liver metastases from colorectal cancer.
Carotid tracer uptake and C-reactive protein: Noh and colleagues investigate the relationship of carotid 18F-FDG uptake on PET/CT to high-sensitivity C-reactive protein levels and Framingham risk scores in a large cohort of asymptomatic adults.
CCTA for SPECT AC maps: Fuchs and colleagues explore the feasibility of attenuation correction of myocardial perfusion imaging with a virtual unenhanced cardiac CT scan synthesized from contrast-enhanced single-source dual-energy coronary CT angiography.
Levodopa response in parkinsonism: Hellwig and colleagues determine whether striatal dopamine D2/D3 receptor binding assessed by 123I-iodobenzamide SPECT is an independent predictor of dopaminergic responsiveness in patients with parkinsonism.
18F-CP-18 radiation dosimetry: Doss and colleagues elucidate biodistribution and estimate normal-organ radiation absorbed doses and effective dose from 18F-CP-18, a tracer under evaluation as a tissue apoptosis marker for PET imaging.
Dosimetry after 166Ho radioembolization: Smits and colleagues assess SPECT and MR imaging–based dosimetry in the first patients treated with 166Ho-poly(l-lactic acid)-microsphere radioembolization for liver malignancies.
11C-laniquidar radiation dose: Postnov and colleagues use whole-body PET to establish the dosimetry of 11C-laniquidar for studies of P-glycoprotein expression in humans.
Radiotracer imaging of PVD: Stacy and colleagues provide an educational overview of currently available imaging modalities for assessing peripheral vascular disease and outline the potential role of targeted imaging of perfusion and angiogenesis in its evaluation.
18F-LMI1195 tumor imaging: Gaertner and colleagues evaluate 18F-LMI1195, an MIBG analog, for detection of pheochromocytoma in a preclinical model of endogenous neuroendocrine tumors.
EFGR targeting in HNSCC: van Dijk and colleagues detail development and characterization of a 111In-cetuximab-F(ab′)2 tracer for imaging epidermal growth factor receptor targeting in patients with advanced head and neck squamous cell carcinomas undergoing dual therapy.
18F-DPA-714 PET and ErPC3 effect: Awde and colleagues monitor the antitumor effect of alkylphosphocholine erufosine treatment in vivo using PET and a translocator protein radioligand with promise as an alternative tracer in human glioma imaging.
Comparing bombesin PET probes: Liu and colleagues describe the development of a clinically translatable bombesin-based PET probe and evaluate the relative effectiveness of labeling with Al18F or 64Cu.
Imaging inflammation in ischemic hearts: Liu and colleagues characterize the kinetic profile of a 99mTc-labeled dual-domain cytokine ligand for SPECT imaging of inflammatory response in an ischemic–reperfused rat heart model.
Preclinical imaging of αvβ6 integrins: John and colleagues report on a highly sensitive, quantifiable, and noninvasive technique for measuring αvβ6 integrin levels within the lung and describe the potential for SPECT/CT in personalizing therapy for patients with pulmonary fibrosis.
18F-FDG kinetics in hypoglycemic mouse brain: Alf and colleagues use 18F-FDG PET to explore the ways in which cerebral glucose transport and phosphorylation change under acute hypoglycemia and the underlying mechanisms of adaptation.
Resveratrol and glucose uptake: Jung and colleagues evaluate the effect of resveratrol on cancer cell glucose metabolism, as assessed by 18F-FDG uptake, and investigate the role of reactive oxygen species in this response.
44Sc-folate for PET imaging: Müller and colleagues provide a rationale and high-yield production and efficient separation method for use of 44Sc as an alternative to 68Ga in imaging and dosimetry before 177Lu-based radionuclide therapy.
Molecular cardiac SPECT quantification: Li and colleagues describe the creation and validation of a new SPECT method for quantitative serial assessment of absolute radiotracer uptake in myocardium.
MIRD Pamphlet No. 24––131I SPECT: Dewaraja and colleagues present the first in a series of isotope-specific guidelines intended to provide guidance on development of protocols for quantitative 131I SPECT in radionuclide therapy applications that require regional and 3D dosimetry.
- © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.